Skip to content

Application of Guduchyadi Anjana(collyrium) in the treatment of distant visual impairment(Myopic Astigmatism).

Assessment of Guduchyadi Anjana in the management of Pratham Patalagata Timira with reference to Myopic Astigmatism- A Randomized Controlled Clinical Trial. - Nil

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/05/066624
Enrollment
80
Registered
2024-05-01
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H538- Other visual disturbances

Interventions

None listed

Sponsors

Dr Shital Kulkarni
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients presenting with classical features of Pratham Patalagata Timira and Myopic Astigmatism. 2. Patients of either sex within the age group of 20-30 years of age. 3. patients having Myopic Astigmatism of - 0.75 to -4.00D(Dioptre).

Exclusion criteria

Exclusion criteria: 1. Ocular pathology like e.g., Cataract, corneal opacity, retinal diseases, iridocyclitis, etc., 2. Patients with systemic diseases like Diabetes mellitus, Hypertension, TB. 3. Patient’s below 20 years and above 30 years of age. 4. Pregnant and lactating women. 5.patients having Myopic Astigmatism above -4.00 D(Dioptre).

Design outcomes

Primary

MeasureTime frame
Guduchyadi Anjana is significantly effective in the management of Pratham Patalagata Timira with reference to Myopic Astigmatism.Timepoint: follow up on day 0th,7th,14th,21th,28th,35th

Secondary

MeasureTime frame
Guduchyadi Anjana is not effective in the management of Pratham Patalagata Timira with reference to Myopic Astigmatism.Timepoint: follow up on day 0th,7th,14th,21th,28th,35th

Countries

India

Contacts

Public ContactDr Nutan Radaye
nutan.radaye.nr@gmail.com9820512695

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026